Rituximab-treated patients had higher serum levels of IL-@ ( @ @ pg/mL vs @ @ pg/mL ; P < @ ) and MIP-@ ( @ @ pg/mL vs @ @ pg/mL ; P < @ ) compared to placebo-treated patients at @ hours after start of infusion .